Improved therapeutic management of women with endometriosis
article
OA: diamond
CC0
⤵ 1 in-corpus citation
Abstract
It was developed and tested a complex drug therapy of women with endometriosis. Within 6 months of the study’s authors are actively watching the 80 women with adenomyosis, which were divided into two groups. The first group of women (n = 42) administered progestin therapy for 6 months – Vissane (dienogest 2 mg). The second group included 38 patients treated with combined therapy: Vissane (dienogest 2 mg) daily for 6 months, Adaptol (mebicar 500 mg) twice a day and Noophen (phenibutum 250 mg) twice a day for three months.The results showed a slightly higher clinical efficacy of progestogen therapy (Visan) in combination with non-hormonal drugs (Adptol and Noophen).
My notes (saved in your browser only)
Condition tags
Citation neighborhood (sparse)
Too few in-corpus citations on either side for a chart; here are the lists.
Cites (3)
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile 2007
- The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro 2001
- Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression 2009
Cited by (1)
References (5)
- Dienogest, a synthetic progestin, inhibits the proliferation of immortalized human endometrial epithelial cells with suppression of cyclin D1 gene expression via openalex
- Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile via openalex
- The inhibitory effect of dienogest, a synthetic steroid, on the growth of human endometrial stromal cells in vitro via openalex
- W1965699572 via openalex
- W2096141938 via openalex
Cited by (1)
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
License: CC0
· commercial use OK